** Shares of telehealth firm Hims & Hers Health HIMS.N slump 16.09% to $24.45 premarket

** Co missed Q1 revenue forecasts and posted an unexpected loss, as its move into branded GLP-1 weight-loss drugs squeezed margins and hurt U.S. sales

** J.P. Morgan trims PT to $33 from $35; maintains an "overweight" stance on the stock

** Brokerage sees that the shift from compounded to Novo-branded GLP-1s was going to create noise in the near-term financials

** Adds, that this lends weight to concerns that the shift to branded products could weigh on co's margin profile

** Co reported a Q1 loss of 40 cents per share, compared with analysts' estimate for a profit of 4 cents per share

** The average rating of 17 analysts covering the stock is "hold" and the median price target is $25 - data compiled by LSEG

** As of last day's close, stock down 10.25% YTD